Clinical treatment of triple negative breast cancer (TNBC) is very poor for lack of effective treatment combination selection. Protein C receptor (PROCR) is a novel cancer stem marker in TNBC patients tumor tissues. Developed based on peptide BP10 with affinity to PROCR as a targeting element, constructing a peptide drug conjugate of BP10 covalently coupling doxorubicin with disulfide bonds. This study demonstrated that the constructed BP10-DOX can selectively target Triplenegative breast cancer cells expressing PROCR and controlled release of DOX in response to the GSH environment. Moreover, BP10-DOX improves the therapeutic efficiency on MDA-MB-231 cells in vitro. Further evidence obtained from in vivo xenograft experiments revealed that administration of BP10-DOX enhanced the antitumor efficacy. This study developed a promising chemotherapy strategy for TNBC.

中文翻译：

---

木马样肽药物偶联物设计与构建在三阴性乳腺癌治疗中的应用。

由于缺乏有效的治疗组合选择，三阴性乳腺癌（TNBC）的临床治疗效果很差。蛋白 C 受体 (PROCR) 是 TNBC 患者肿瘤组织中的一种新型癌症干标志物。基于对PROCR具有亲和力的肽BP10作为靶向元件开发，构建BP10与阿霉素与二硫键共价偶联的肽药物偶联物。这项研究表明，构建的 BP10-DOX 可以选择性地靶向表达 PROCR 的三阴性乳腺癌细胞，并响应 GSH 环境控制释放 DOX。此外，BP10-DOX 提高了体外MDA-MB-231 细胞的治疗效率。从体内获得的进一步证据异种移植实验表明，BP10-DOX 的给药增强了抗肿瘤功效。这项研究为 TNBC 制定了一种有前景的化疗策略。